PAR-13-007 Early-Stage Pharmacological Validation of Novel Targets and Accompanying Pre-Therapeutic Leads for Diseases of Interest to the NIDDK (R01)

PAR-13-007 Early-Stage Pharmacological Validation of Novel Targets and Accompanying Pre-Therapeutic Leads for Diseases of Interest to the NIDDK (R01)

Letter of Intent Due 30 days prior to Application Receipt Date
Application Receipt Dates: Standard dates apply
Expiration Date: March 8, 2016